Atropisomerism in Action: The Sotorasib Story
When a Biaryl Bond Became a Drug-Design Advantage—and a Development Challenge Introduction: What if a “rotatable bond” could influence the fate of a drug? I recently came across a fascinating perspective written by scientists directly involved in the development of sotorasib, a KRAS G12C inhibitor exhibiting atropisomerism. Their article, “Addressing Atropisomerism in the Development of …